Sign in
Taking peopleNo phase

Optimising Kangaroo Care to Reduce Neonatal Severe Infection/Sepsis and Resistant Bacterial Colonisation Among High-risk Infants in NICU.

Key facts

Who runs it
PENTA Foundation
Where
Greece, Italy, Spain, Switzerland, and United Kingdom24 sites in 5 countriesChoose a country to see its sites
Trial code
Status
Recruiting
People taking part
3,080 people, planned
Started
28 May 2024
Planned end
May 2026
Type of study
Interventional, 2 groupsOne group gets no study treatment, for comparison.
Treatments tested
  • Optimised kangaroo care
Record updated
25 March 2026

Who can take part

Age
Up to 32 weeks
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 6 criteriaShow less

Who can take part

  • Site level; 1a. Neonatal unit that provide routinely cares for extremely premature infants (<28 weeks' gestation); 1b. Minimum capacity of 12 beds; 1c. Access to a -70 to -80°C freezer for storage of research samples; 1d. Willing to implement optimised KC if allocated to the intervention group; 1e. Willing to commit to offering the minimum expected target duration or an increase of 50% if neonatal unit is already offering >67% of the minimum expected target duration, if allocated to the intervention arm; 1f. Prepared to implement NeoIPC surveillance
  • g. Adequate resources and expertise and approvals from relevant Research Ethics Committees, as appropriate
  • Infant level; 2a. All high-risk infants (born at <32 weeks' gestation) admitted to participating neonatal units, regardless of complexity of care, anticipated hospitalisation duration, room type, or whether admitted directly after birth

Who cannot take part

  • a. Participation in other research that could directly influence the study intervention or outcomes
  • a. Average StSC duration already exceeding 18 hours per day
  • a. Anticipated major changes in resistant bacterial colonisation pressure during the study; 2 Infant level 2a. No infant-level exclusion criteria for data collection. We exclude infants from individual data and sample collection if their parents or legal guardians do not provide written informed consent. These infants contribute to cluster-aggregated outcomes

This trial has no sites in United States.

It has sites in 5 countries. Choose a country to see its sites.

About the trial

What the trial wants to find out

NeoDeco is a pragmatic, multicenter, parallel-group, cluster-randomised hybrid effectiveness-implementation trial designed to evaluate the impact of implementing optimised Kangaroo Care (KC) at the unit level compared to standard care in high-technology neonatal units. The trial includes a baseline period, a wash-in phase, and a staggered randomisation approach. The primary focus of the NeoDeco study is on high-risk preterm infants born at less than 32 weeks' gestational age, a population particularly vulnerable to hospital-acquired infections and sepsis during their initial hospital stay. By investigating hospital-acquired infections specifically, the study targets the period during which optimised KC practices are likely to have the most significant impact.

The 2 groups in the trial

  • Optimised kangaroo careTreatment being tested

    The sites randomised in this group will adapt the study intervention consisting of: Component 1: Skin-to-skin contact for optimised KC, describes the targeted level of early, repeated and sustained skin-to-skin contact (StSC) considered to represent optimised KC in a high-technology neonatal unit environment in which KC is already offered as part of routine care. Component 2: Implementation Support aims to engage clinical staff in the neonatal unit who are involved in implementing StSC as part of optimised KC.

  • Standard of CareNo study treatment, for comparison

    The sites randomised in this group will follow the standard care, including KC and StSC sessions, treatment of severe infections/sepsis and infection prevention and control measures based on current routine local practice. Standard care in all participating NICUs already includes KC but without specific activities to ensure this is implemented according to international best practice recommendations.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Optimising Kangaroo Care to Reduce Neonatal Severe Infection/Sepsis and Resistant Bacterial Colonisation Among High-risk Infants in Neonatal Intensive Care: a Pragmatic, Multicentre, Parallel Cluster Randomised Hybrid Implementation-effectiveness Study.
Record updated
25 March 2026